Stereotactic ablative radiotherapy for small lung tumors with a moderate dose Favorable results and low toxicity

• Published in: Strahlentherapie und Onkologie Vol. 189; no. 1; pp. 33 - 40
• Main Authors: Duncker-Rohr, V., Nestle, U., Momm, F., Prokic, V., Heinemann, F., Mix, M., Reusch, J., Messmer, M.-B., Marschner, N., Waller, C.F., Weber, W.A., Grosu, A.-L.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 2013
• Subjects: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - surgery; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - secondary; Lung Neoplasms - surgery; Lung Volume Measurements; Male; Medicine; Medicine & Public Health; Middle Aged; Multimodal Imaging; Neoplasm Staging; Oncology; Original Article; Positron-Emission Tomography; Radiosurgery - methods; Radiotherapy; Tomography, X-Ray Computed; Toxizität; Metastase; Nichtkleinzelliges Bronchialkarzinom; Toxicity; Stereotactic ablative radiotherapy; Non-small cell lung cancer; Optimum dose schedule; Optimales Dosisschema; Metastasis; Stereotaktische ablative Strahlentherapie
• ISSN: 0179-7158; 1439-099X
• DOI: 10.1007/s00066-012-0224-y

Background Stereotactic ablative body radiotherapy (SBRT, SABR) is being increasingly applied because of its high local efficacy, e.g., for small lung tumors. However, the optimum dosage is still under discussion. Here, we report data on 45 lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 39 patients treated between 2009 and 2010 by SABR. Patients and methods SABR was performed with total doses of 35 Gy (5 fractions) or 37.5 Gy (3 fractions) prescribed to the 60% isodose line encompassing the planning target volume. Three-monthly follow-up CT scans were supplemented by FDG-PET/CT if clinically indicated. Results The median follow-up was 17 months. Local progression-free survival rates were 90.5% (all patients), 95.0% (NSCLC), and 81.8% (metastases) at 1 year. At 2 years, the respective local progression-free survival rates were 80.5%, 95.0%, and 59.7%. Overall survival rates were 71.1% (all patients), 65.4% (NSCLC), and 83.3% (metastases) at 1 year. Overall survival rates at 2 years were 52.7%, 45.9%, and 66.7%, respectively. Acute side effects were mild. Conclusion With the moderate dose schedule used, well-tolerated SABR led to favorable local tumor control as in other published series. Standardization in reporting the dose prescription for SABR is needed to allow comparison of different series in order to determine optimum dosage.